Gather additional industry and technical information from our repository of resources and educational content.

Filter 142 Results

Application
Technology
Service
Content Type

Executive Summary: in vitro Test Methodologies for Bioavailability Enhancement

This executive summary discusses in vitro methodologies used at Lonza for the characterization of bioavailability enhancing formulations, as well as criteria for selecting the right in vitro method based on compound properties and dose. To learn more, please download our executive summary.
Authors: Aaron Stewart
Publish Date: 23-Jul-2020

Executive Summary: Technology Selection for Bioavailability Enhancement Programs

Due to the growing incidence of low drug solubility in the pharmaceutical discovery and development pipeline the number of enabling technologies that are employed to improve oral drug absorption and bioavailability (BA) are also growing. Most commonly utilized are particle size reduction, amorphous solid dispersions and lipid-based technologies. Facilitated by advances in predictive methodologies, amorphous solid dispersions have become the most prevalent commercially deployed BA technology. This executive summary provides an overview of this topic.
Authors: Dr. David Lyon
Publish Date: 23-Jul-2020

Lonza Small Molecule Capabilities: Drug Substance to Drug Product, Parenteral to Oral

Lonza Pharma and Biotech is a multi-national contract development & manufacturing organization (CDMO) that specializes in difficult-to-manufacture drug substance, drug product intermediates and drug product. In this introductory 30-minute interactive discussion, David Lyon, Sr. Fellow, Research, will highlight Lonza’s capabilities across the spectrum of drug development inclusive of parenteral, inhaled, and oral drug delivery. This introductory discussion will lead the way to future discussions taking deep dives into the highlighted areas.
Authors: Dr. David Lyon
Publish Date: 23-Jul-2020

Specialized Clinical Services for Complex Clinical Studies

This webinar provides an overview of Lonza's clinical services, inclusive of integrated first-in-human solutions, which can effectively support accelerated timelines. Selected case studies are presented that demonstrate best practices in complex packaging and direct-to-patient supply. To learn more, please view our presentation.
Authors: David Dreifke, Dr. David Lyon
Publish Date: 23-Jun-2020

Lipid-Based Formulations for Early-Stage Clinical Trials

For certain molecules, the most appropriate technology for bioavailability enhancement and accelerated development will be lipid-based formulations (LBF), supported by in silico development tools. Senior Formulation and Product Development Scientists analyze the potential benefits and applications of lipid/liquid-based formulations and how they may reduce timelines to clinical trials. To learn more, please download our whitepaper.
Authors: Annabel Igonin, Jenifer Mains
Publish Date: 05-Jun-2020

Technology Selection for Oral Bioavailability Enhancement Programs

Due to the growing incidence of low drug solubility in the pharmaceutical discovery and development pipeline the number of enabling technologies that are employed to improve oral drug absorption and bioavailability (BA) are also growing. Most commonly utilized are particle size reduction, amorphous solid dispersions and lipid-based technologies. Facilitated by advances in predictive methodologies, amorphous solid dispersions have become the most prevalent commercially deployed BA technology. To learn more, please download our whitepaper.
Authors: Dr. David Lyon
Publish Date: 04-Jun-2020

High-Loaded Dosage Forms: Novel Platform Expands Dispersion Utility

Spray-dried amorphous solid dispersions (ASDs) show enormous promise in the delivery of drug compounds with low solubility. A novel platform expands the utility of this approach, enabling creation of ASD solid dosage forms with high drug loadings to meet patient needs. To learn more, please download our whitepaper.
Authors: Dr. Deanna Mudie
Publish Date: 04-Jun-2020

Oral Multiparticulate Technologies

Multiparticulates offer a number of advantages, including optimized GI tract distribution, predictable gastrointestinal (GI) transit, formulation flexibility, and protection against dose dumping concerns.  Because of their small size, shape and composition, multiparticulates also offer wide flexibility in the choice of manufacturing process and final dosage form. Lonza’s oral multiparticulate technologies enable you to address a broad range of formulation needs.To learn more, please view our technical brief.
Publish Date: 05-May-2020

Lonza Regulatory Services - Small Molecules

Today timelines for drug development are getting shorter and shorter with 40% of approvals being expedited. In order to keep up with the tempo and stay ahead of competition every link of the chain from research, drug substance/drug product development and manufacturing needs to be in-sync. Timely and proper documentation and communication with the appropriate regulatory authorities can make a difference. To learn more, please read our technical brief.
Authors: John McGuire, Jakob Bonde
Publish Date: 05-May-2020

Modified and Targeted Delivery Technologies

Achieving precise drug-delivery profiles can present substantial formulation challenges. This technical brief describes Lonza's numerous specialized technologies for modified and targeted delivery of drug compounds. These technologies can be used alone and with other enabling technologies to modulate the pharmacokinetics of drug compounds and optimize drug performance and therapeutic effect. To learn more, please read our technical brief.
Publish Date: 05-May-2020